Research Topics
| John C BreitnerSummaryAffiliation: University of Washington Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
NSAIDs and Alzheimer's disease: how far to generalise from trials?John C S Breitner
GRECC S 182, VA Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA 98108, USA
Lancet Neurol 2:527. 2003- Dementia--epidemiological considerations, nomenclature, and a tacit consensus definitionJohn C S Breitner
Geriatric Research Education and Clinical Center, VA Puget Sound Health Care System, and Division of Geriatric Psychiatry, University of Washington School of Medicine, Seattle, WA 98108, USA
J Geriatr Psychiatry Neurol 19:129-36. 2006..Beyond this description, our knowledge of pathology and, ultimately, the etiology of individual cases is extremely variable. Whatever its antecedents, syndromically defined dementia presents a looming public health crisis... 
Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohortJ C S Breitner
Geriatric Research Education and Clinical Center, Department of Veterans Affairs Medical Center, VA Puget Sound Health Care System, Seattle, WA 98108, USA
Neurology 72:1899-905. 2009..Nonsteroidal anti-inflammatory drugs (NSAIDs) may prevent Alzheimer dementia (AD)...- Statin use and the risk of incident dementia: the Cardiovascular Health StudyThomas D Rea
Department of Medicine, University of Washington, Seattle 98101, USA
Arch Neurol 62:1047-51. 2005..Statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce cardiovascular risk through mechanisms that might affect the development of dementia... - Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's diseaseThomas J Montine
Department of Pathology, University of Washington, Seattle, WA 98104, USA
J Alzheimers Dis 8:359-67. 2005..In addition, measurement of CSF F2-IsoPs can increase the accuracy of laboratory-based classification of geriatric dementias, and have been used to assess objectively the response to anti-oxidant interventions in AD... - Incidence and prevalence of dementia in the Cardiovascular Health StudyAnnette L Fitzpatrick
Department of Epidemiology, University of Washington, Seattle, Washington 98115, USA
J Am Geriatr Soc 52:195-204. 2004..To estimate the incidence and prevalence of dementia, Alzheimer's disease (AD), and vascular dementia (VaD) in the Cardiovascular Health Study (CHS) cohort... - Antioxidant vitamin supplement use and risk of dementia or Alzheimer's disease in older adultsShelly L Gray
School of Pharmacy, University of Washington, Seattle, Washington 98195, USA
J Am Geriatr Soc 56:291-5. 2008..To examine whether use of vitamins C or E alone or in combination was associated with lower incidence of dementia or Alzheimer's disease (AD)... - Free radical damage to cerebral cortex in Alzheimer's disease, microvascular brain injury, and smokingJoshua A Sonnen
Department of Pathology, University of Washington, Seattle, USA
Ann Neurol 65:226-9. 2009.... - Cerebrospinal fluid biomarkers in mild cognitive impairment and dementiaJoshua A Sonnen
Department of Pathology, Division of Neuropathology, University of Washington, Seattle, WA 98104 2420, USA
J Alzheimers Dis 19:301-9. 2010..A multimodal approach that brings independent information from risk factor assessment, neuroimaging, and biomarkers may soon guide physicians in the early diagnosis and management of cognitive impairment in the elderly... - Age-varying association between statin use and incident Alzheimer's diseaseGe Li
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, USA
J Am Geriatr Soc 58:1311-7. 2010..To determine whether risk reduction of statins for Alzheimer's disease (AD) varies by age or presence of apolipoprotein E (APOE) epsilon4 allele... - Age-varying association between blood pressure and risk of dementia in those aged 65 and older: a community-based prospective cohort studyGe Li
Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA
J Am Geriatr Soc 55:1161-7. 2007..To assess variation in the association between blood pressure (BP) and risk for dementia across a spectrum of older ages and to examine BP changes before dementia onset... - Histamine-2 receptor antagonist use and incident dementia in an older cohortShelly L Gray
School of Pharmacy, University of Washington, Seattle, Washington, USA
J Am Geriatr Soc 59:251-7. 2011..To examine whether histamine-2 receptor antagonist medications (H2RAs) are associated with a lower incidence of all-cause dementia or Alzheimer's disease (AD), as some studies have suggested... - Biomarkers for cognitive impairment and dementia in elderly peopleJoshua A Sonnen
Department of Pathology, Division of Neuropathology, University of Washington, Seattle, WA 98104, USA
Lancet Neurol 7:704-14. 2008..An approach that efficiently combines independent information from risk-factor assessment, neuroimaging measures, and biomarkers might soon guide clinicians in the early diagnosis and management of cognitive impairment in elderly people... - Apolipoprotein E genotype and mortality: findings from the Cache County StudyKathleen M Hayden
Center for the Study of Aging and Human Development, Duke University Medical Center, Durham, North Carolina
J Am Geriatr Soc 53:935-42. 2005..To evaluate the association between apolipoprotein E (apo E) epsilon4 and mortality, the population attributable risk for mortality with epsilon4, and relative contributions of cardiovascular disease (CVD) and Alzheimer's disease (AD)... - Cognitive function over time in the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT): results of a randomized, controlled trial of naproxen and celecoxibBarbara K Martin
Arch Neurol 65:896-905. 2008..CONCLUSIONS: Use of naproxen or celecoxib did not improve cognitive function. There was weak evidence for a detrimental effect of naproxen... - A population study of Alzheimer's disease: findings from the Cache County Study on Memory, Health, and AgingJoAnn T Tschanz
Department of Psychology, Center for Epidemiologic Studies, Utah State University, Logan 84322 4440, USA
Care Manag J 6:107-14. 2005.... - Reduced incidence of AD with NSAID but not H2 receptor antagonists: the Cache County StudyPeter P Zandi
Department of Mental Hygiene, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Neurology 59:880-6. 2002..Recently initiated randomized trials of NSAID for primary prevention of AD are therefore unlikely to show effects with treatment until participants have been followed for several years... - Vascular risk factors for incident Alzheimer disease and vascular dementia: the Cache County studyKathleen M Hayden
Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27705, USA
Alzheimer Dis Assoc Disord 20:93-100. 2006..Future studies should focus on specific causal pathways for each of these factors with regard to sex to determine if sex differences in the prevalence of vascular factors have an influence on sex differences in dementia risk... - Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County StudyPeter P Zandi
Department of Mental Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA
Arch Gen Psychiatry 62:217-24. 2005..Prior reports suggest reduced occurrence of dementia and Alzheimer disease (AD) in statin users, but, to our knowledge, no prospective studies relate statin use and dementia incidence... - Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County StudyMartin Steinberg
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Int J Geriatr Psychiatry 23:170-7. 2008..Neuropsychiatric symptoms are nearly universal in dementia, yet little is known about their longitudinal course in the community... - Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County StudyAra S Khachaturian
Khachaturian and Associates Inc, Potomac, MD, USA
Arch Gen Psychiatry 61:518-24. 2004..APOE is a strong genetic risk factor for AD... - Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County StudyPeter P Zandi
Department of Mental Health, Bloomberg School of Public Health, The Johns Hopkins University, Hampton House Room 857, 624 N Broadway, Baltimore, MD 21205, USA
Arch Neurol 61:82-8. 2004..Antioxidants may protect the aging brain against oxidative damage associated with pathological changes of Alzheimer disease (AD)... - Better cognitive performance in elderly taking antioxidant vitamins E and C supplements in combination with nonsteroidal anti-inflammatory drugs: the Cache County StudyMajid Fotuhi
Department of Neurology, Johns Hopkins University School of Medicine, and Center for Memory and Brain Health, LifeBridge Health Brain and Spine Institute, Baltimore, MD, USA
Alzheimers Dement 4:223-7. 2008..05). These results suggest that among elderly individuals with an APOE epsilon4 allele, there is an association between using antioxidant supplements in combination with NSAIDs and less cognitive decline over time... - Hormone replacement therapy and incidence of Alzheimer disease in older women: the Cache County StudyPeter P Zandi
Department of Mental Hygiene, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD, USA
JAMA 288:2123-9. 2002..55 [95% CI, 0.21-1.23]). CONCLUSIONS: Prior HRT use is associated with reduced risk of AD, but there is no apparent benefit with current HRT use unless such use has exceeded 10 years... - Characteristics of a two-stage screen for incident dementiaKathleen M Hayden
Department of Menral Hygiene, The Johns Hopkins University, Bloomberg School of Public Health, Baltimore, MD 21205, USA
J Clin Epidemiol 56:1038-45. 2003..CONCLUSIONS: The improved specificity of the two-stage approach offers economies that are attractive, particularly if sensitivity can be enhanced, for example, by examination of a high-risk validation sample... - The epidemiology of psychosis in dementiaIracema Leroi
Neuropsychiatry Service, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA
Am J Geriatr Psychiatry 11:83-91. 2003..CONCLUSION: The profile of delusions and hallucinations seen is different from that seen in schizophrenia, further supporting the hypothesis that AD-associated psychosis is a distinct phenomenological syndrome... - The incidence of mental and behavioral disturbances in dementia: the cache county studyMartin Steinberg
Johns Hopkins Hospital, Baltimore, MD 21287, USA
J Neuropsychiatry Clin Neurosci 15:340-5. 2003..These results argue for a routine assessment of psychiatric disturbances in all patients with dementia, even among those who have never experienced symptoms of mental or behavioral disturbances... 
Regional atrophy of the corpus callosum in dementiaBradley J Hallam
The Travis Research Institute, Center for Biopsychosocial Research, Fuller Graduate School of Psychology, Pasadena, California, USA
J Int Neuropsychol Soc 14:414-23. 2008..Findings suggest that dementia-related CC atrophy occurs primarily in the anterior and posterior portions...- Statin therapy is associated with reduced neuropathologic changes of Alzheimer diseaseGeorge J Siegel
Neurology 71:383; author reply 383. 2008 - Paranoid psychoses in old age: much more common than previously thought?John C S Breitner
Bloomberg School of Public Health, Johns Hopkins University, 624 N Broadway, Hampton House, Room 850, Baltimore, MD 21205, USA
Arch Gen Psychiatry 59:60-1. 2002 - Vascular factors and risk for neuropsychiatric symptoms in Alzheimer's disease: the Cache County StudyKatherine A Treiber
Department of Psychology, Utah State University, Logan, U S A
Int Psychogeriatr 20:538-53. 2008..To examine, in an exploratory analysis, the association between vascular conditions and the occurrence of neuropsychiatric symptoms (NPS) in a population-based sample of incident Alzheimer's disease (AD)... - Chronic disease long-term drug prevention trials: lessons from the Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT)Curtis L Meinert
Department of Epidemiology, Bloomberg School of Public Health, The Johns Hopkins University, Baltimore, MD, USA
Alzheimers Dement 4:S7-S14. 2008.... - Church attendance and new episodes of major depression in a community study of older adults: the Cache County StudyMaria C Norton
Department of Family, Consumer and Human Development, Cache County Study on Memory Health and Aging, Utah State University, 4440 Old Main Hill, Logan, UT 84322 4440, USA
J Gerontol B Psychol Sci Soc Sci 63:P129-37. 2008..28-0.92). Results suggest that there may be a threshold of church attendance that is necessary for a person to garner long-term protection from depression. We discuss sociological factors relevant to LDS culture... - A roadmap for the prevention of dementia: the inaugural Leon Thal SymposiumZaven S Khachaturian
Alzheimers Dement 4:156-63. 2008 - The trialist, meta-analyst, and journal editor: lessons from ADAPTBarbara K Martin
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
Am J Med 120:192-3. 2007 - Risk of mortality with vitamin E supplements: the Cache County studyKathleen M Hayden
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, USA
Am J Med 120:180-4. 2007..We sought to determine whether these mortality risks with vitamin E reflect adverse consequences of its use in the presence of cardiovascular disease... - An adaptation of the modified mini-mental state examination: analysis of demographic influences and normative data: the cache county studyJoAnn T Tschanz
Department of Psychology, Utah State University, Logan, Utah 84322 4440, USA
Neuropsychiatry Neuropsychol Behav Neurol 15:28-38. 2002..To present a new version of the Modified Mini-Mental State Examination (3MS-R), provide normative information extending to individuals in the 10th decade, and examine the effects of demographic variables on test performance... - H2 histamine receptor blockade in the treatment of Alzheimer disease: a randomized, double-blind, placebo-controlled trial of nizatidineMichelle C Carlson
Department of Mental Hygiene, and Center on Aging and Health, The Johns Hopkins University School of Public Health, Baltimore, Maryland 21205, USA
Alzheimer Dis Assoc Disord 16:24-30. 2002..To evaluate the efficacy of nizatidine, a histamine H2-blocking drug, in delaying the progression of cognitive impairment in older adults with Alzheimer disease (AD)... - Is pharmacological prevention of Alzheimer's a realistic goal?Peter P Zandi
Department of Mental Hygiene, Bloomberg School of Public Health, Johns Hopkins University, Hampton House 884, 624 N Broadway, Baltimore, MD 21205, USA
Expert Opin Pharmacother 3:365-80. 2002.... - White matter lesions, quantitative magnetic resonance imaging, and dementiaErin D Bigler
Bringham Young University, Provo, Utah, USA
Alzheimer Dis Assoc Disord 16:161-70. 2002..There were no significant qualitative or quantitative findings related to presence of the epsilon4 allele and MMSE performance. The role of WMLs in aging and dementia is discussed... - Alzheimer disease in Turkey tooJohn C S Breitner
Alzheimer Dis Assoc Disord 17:137-8. 2003 - Effects of estrogen plus progestin on risk of dementiaJohn C S Breitner
JAMA 290:1706-7; author reply 1707-8. 2003 - "At my wits' end": neuroticism and dementiaJohn C S Breitner
Neurology 61:1468-9. 2003 - The persistence of neuropsychiatric symptoms in dementia: the Cache County StudyMartin Steinberg
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
Int J Geriatr Psychiatry 19:19-26. 2004..To estimate the 18-month persistence of neuropsychiatric symptoms in dementia in a population-based sample, and to compare the severity of neuropsychiatric symptoms at baseline to the severity at 18-month follow-up... - Nonsteroidal anti-inflammatory drugs for the prevention of Alzheimer's disease: a systematic reviewChristine A Szekely
Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
Neuroepidemiology 23:159-69. 2004..The purpose of this meta-analysis is to summarize and evaluate available evidence regarding exposure to nonaspirin NSAIDs and risk of Alzheimer's disease using meta-analyses of published studies... - Population-based study of medical comorbidity in early dementia and "cognitive impairment, no dementia (CIND)": association with functional and cognitive impairment: The Cache County StudyConstantine G Lyketsos
Division of Geriatric Psychiatry and Neuropsychiatry, Dept of Psychiatry and Behavioral Sciences, School of Medicine, The Johns Hopkins University, Johns Hopkins Hospital, Baltimore, MD 21287, USA
Am J Geriatr Psychiatry 13:656-64. 2005..Authors investigated medical comorbidity in persons with dementia and "Cognitive Impairment, No Dementia" (CIND)... - Is cholesterol a culprit in Alzheimer's disease?D Larry Sparks
Laboratory for Neurodegenerative Disease Research, Sun Health Research Institute, Sun City, Arizona 85351, USA
Int Psychogeriatr 15:153-9. 2003..Nevertheless, the foregoing suggests that routine monitoring and intervention for elevated cholesterol levels among the elderly could promote more than a healthy heart... - Three-year incidence of first-onset depressive syndrome in a population sample of older adults: the Cache County studyMaria C Norton
Department of Family, Consumer and Human Development, Utah State University, Logan, 84322, USA
Am J Geriatr Psychiatry 14:237-45. 2006.... - Antihypertensive medication use and incident Alzheimer disease: the Cache County StudyAra S Khachaturian
Khachaturian and Associates Inc, Potomac, MD, USA
Arch Neurol 63:686-92. 2006..CONCLUSIONS: These data suggest that AH medications, and specifically potassium-sparing diuretics, are associated with reduced incidence of AD. Because the latter association is a new finding, it requires confirmation in further study... - A population-based study of the association between coronary artery bypass graft surgery (CABG) and cognitive decline: the Cache County studyConstantine G Lyketsos
Division of Geriatric Psychiatry and Neuropsychiatry, Department of Psychiatry and Behavioral Sciences, School of Medicine, The Johns Hopkins University, Baltimore, MD, USA
Int J Geriatr Psychiatry 21:509-18. 2006..This decline is small and its clinical significance is uncertain. We could not find an association between CABG and decline in the first five post-operative years... - Duke Twins Study of Memory in Aging in the NAS-NRC Twin RegistryBrenda L Plassman
Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC 27701, USA
Twin Res Hum Genet 9:950-7. 2006..We provide an overview of the study's methodology and describe the focus of recent research... - Double placebo design in a prevention trial for Alzheimer's diseaseBarbara K Martin
Department of Epidemiology, Center for Clinical Trials, Bloomberg School of Hygiene and Public Health, The Johns Hopkins University, 615 N Wolfe Street, Baltimore, MD 21205, USA
Control Clin Trials 23:93-9. 2002..The authors outline the placebo designs considered in ADAPT, discuss their advantages and disadvantages, and provide their rationale for and the consequences of the selection of the double placebo design...
Research Grants
- PREVENTION OF ALZHEIMER DEMENTIA & COGNITIVE DECLINEJohn Breitner; Fiscal Year: 2006..25 to 4 years of observation and a final analysis. As a secondary outcome, we will examine the trajectory of cognitive scores to assess ARCD. ..
- Prostaglandins & Oxidative Damage in ADAPT ParticipantsJohn Breitner; Fiscal Year: 2006..These studies will provide important insights into the mechanisms by which NSAIDs prevent AD. ..
- EPIDEMIOLOGY OF DEMENTIA IN CACHE COUNTY, UTAHJohn Breitner; Fiscal Year: 2001..These exposures will receive emphasis in the incidence phase of the study as a likely preface to randomized primary prevention trials. ..
- Prostaglandins & Oxidative Damage in ADAPT ParticipantsJohn Breitner; Fiscal Year: 2007..These studies will provide important insights into the mechanisms by which NSAIDs prevent AD. ..